The Impacts of Episcleral Plaque Brachytherapy on Ocular Motility.

J Binocul Vis Ocul Motil

Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.

Published: October 2021

: To investigate the effect of various factors on ocular motility disturbance after episcleral plaque brachytherapy with Ruthenium 106 (Ru).: Twenty consecutive patients who underwent plaque brachytherapy for all types of intraocular tumors were included in this interventional prospective case series. Ruthenium-106 was used with a mean total dose of 93.2 ± 21.2 Gy toward the tumor apex. Full orthoptic examinations were performed before and after the surgery.: The average follow-up time was 6 months (range: 4-9 months). Two (10%) out of 20 patients developed exotropia. The mean age of patients without strabismus was higher than the patients with strabismus (49.8 ± 10.7 years compared to 23 ± 4.2 years, respectively) ( = .011). Strabismus was observed in the patients who had tumors with larger apical diameters (7.6 ± 2 mm compared to 4.1 ± 0.9 mm, respectively) ( = .021). The mean radiation dose to the tumor base in the group with strabismus was higher than the group without motility disturbance (1046.5 ± 604.1 Gy compared to 384.3 ± 175.3, respectively) ( = .021). Most tumors were located in the inferotemporal fundus (30%), followed by supratemporal location (25%), supranasal (10%), and macular region (10%). A higher percentage of patients with postoperative strabismus underwent muscle manipulation compared to the patients who did not develop this complication (100% compared to 38.9%).: Manipulation of the extraocular muscles, high doses of radiation, and low vision could cause strabismus after episcleral plaque brachytherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1080/2576117X.2021.1902911DOI Listing

Publication Analysis

Top Keywords

plaque brachytherapy
16
episcleral plaque
12
ocular motility
8
motility disturbance
8
patients strabismus
8
strabismus higher
8
patients
7
strabismus
6
compared
5
impacts episcleral
4

Similar Publications

Plaque brachytherapy has been used in the management of small to medium-sized choroidal melanomas for the past few decades. As the inferior oblique muscle lies in close relation to the macula, the placement procedure of plaques often involves sacrificing the inferior oblique muscle, especially in cases of macular or perimacular choroidal melanomas. In this study, we have described a simple maneuver to preserve the inferior oblique muscle.

View Article and Find Full Text PDF

Oncological principles in the management of ocular surface squamous neoplasia - A Review.

Indian J Ophthalmol

February 2025

Ocular Oncology Service, Centre for Sight, Hyderabad, Telangana, India.

Ocular surface squamous neoplasia (OSSN) is the most common neoplasia of the anterior segment. Accurate and timely diagnosis, including detailed clinical assessment and imaging, is essential to ascertain the extent of the disease. The gold standard treatment for OSSN has evolved over the years, transitioning from wide-margin surgical excision using the "no-touch" technique to topical immunotherapy, plaque brachytherapy, and targeted immunotherapy.

View Article and Find Full Text PDF

Purpose: To evaluate the efficacy of ultrasound-guided ruthenium (Ru 106) plaque brachytherapy for treatment of exudative retinal detachment in diffuse choroidal haemangioma (DCH).

Methods: Retrospective analysis of four paediatric patients treated with ultrasound-guided Ru 106 plaque brachytherapy for DCH with total exudative retinal detachment directed to the thickest part of the DCH. A dose of 40 Gy to the tumour apex was delivered in all patients.

View Article and Find Full Text PDF

Purpose: Uveal melanoma (UM) is the most common primary ocular malignancy. The size and location of the tumor are decisive for brachytherapy with the β-emitting ruthenium-106 (Ru-106) plaque. The treatment of juxtapapillary and juxtafoveolar UM may be challenging because of the proximity or involvement of the macula and optic nerve and high recurrence rates.

View Article and Find Full Text PDF

A retrospective study on ruthenium-106 and strontium-90 eye-plaques treatment for retinoblastoma: 16-years clinical experience.

Brachytherapy

January 2025

Ocular Oncology and Radiology Department, S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia.

Purpose: To retrospectively evaluate the efficacy of plaque brachytherapy for the treatment of retinoblastoma.

Methods: We retrospectively reviewed the clinical records of 163 patients (186 eyes, 333 tumors) treated with brachytherapy (Ru or Sr plaques) for intraocular retinoblastoma between November 2007 and August 2023.

Results: Complete tumor control was achieved in 273 tumors (82%).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!